Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill targets aggressive tumors with genetic flaw

NCT ID NCT06710847

Ongoing Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests an experimental oral drug (GSK4418959) in adults with advanced solid tumors that have specific genetic changes (dMMR or MSI-H). The drug works by blocking a protein (WRN) that these tumors need to survive. The study aims to see if the drug, alone or with another cancer medicine, can shrink tumors and is safe. About 14 participants will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLON CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colon carcinoma colonic neoplasm colorectal cancer colorectal neoplasm endometrial cancer endometrium neoplasm mismatch repair cancer syndrome 1 rectal cancer rectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLON CANCER ENDOMETRIAL CANCER NEOPLASMS, COLORECTAL RECTAL CANCER SOLID TUMOR

Contacts and locations

Locations

  • GSK Investigational Site

    Los Angeles, California, 90095, United States

  • GSK Investigational Site

    Denver, Colorado, 80218, United States

  • GSK Investigational Site

    Detroit, Michigan, 48201, United States

  • GSK Investigational Site

    New York, New York, 10016, United States

  • GSK Investigational Site

    Philadelphia, Pennsylvania, 19104, United States

  • GSK Investigational Site

    Philadelphia, Pennsylvania, 19107, United States

  • GSK Investigational Site

    Melbourne, Victoria, 3000, Australia

  • GSK Investigational Site

    Brussels, 1200, Belgium

  • GSK Investigational Site

    Ghent, 9000, Belgium

  • GSK Investigational Site

    Leuven, 3000, Belgium

  • GSK Investigational Site

    Chiba, 277-8577, Japan

  • GSK Investigational Site

    Shizuoka, 411-8777, Japan

  • GSK Investigational Site

    Tokyo, 104-0045, Japan

  • GSK Investigational Site

    Tokyo, 135-8550, Japan

  • GSK Investigational Site

    Amsterdam, 1066 CX, Netherlands

  • GSK Investigational Site

    Daegu, 41404, South Korea

  • GSK Investigational Site

    Gyeonggi-do, 10408, South Korea

  • GSK Investigational Site

    Seoul, 03080, South Korea

  • GSK Investigational Site

    Barcelona, 08023, Spain

  • GSK Investigational Site

    Barcelona, 08035, Spain

  • GSK Investigational Site

    Madrid, 28040, Spain

  • GSK Investigational Site

    Málaga, 29010, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.